NCT00998361Unknown2 期
Hematopoietic Stem Cell Transplantation From HLA Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 140
- 试验地点
- 2
- 主要终点
- Progression Free Survival (PFS) a 12 months from the enrollment higher than 30% for the patients submitted to allogeneic stem cell transplantation in front of the patients who received conventional chemotherapy.
研究概览
简要总结
This is a perspective multicentric study for the treatment of patients aged equal or less than 60 years and submitted to an allogeneic hematopoietic stem cell transplantation from an HLA compatible related or unrelated donor because affected by resistent or refractory or relapsed after autologous stem cell transplantation Ewing Sarcoma or Soft tissues sarcoma who did not benefit from conventional therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Month 至 60 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 0-60 years.
- •Performance status according to Karnofsky score > 70%
- •Normal liver function
- •Normal renal function
- •Normal cardiac function
- •Informed consent
- •Availability of an HLA compatible Donor
排除标准
- •Absence of at least one of the inclusion criteria
结局指标
主要结局
Progression Free Survival (PFS) a 12 months from the enrollment higher than 30% for the patients submitted to allogeneic stem cell transplantation in front of the patients who received conventional chemotherapy.
时间窗: 12 months from the enrollement
次要结局
- Transplant related mortality(12 months after the enrollement of the first patients)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in SwedenMultiple Sclerosis, Relapsing-RemittingMultiple SclerosisNCT05029206Uppsala University174
已完成
不适用
Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant RecipientsVaccinationHematopoietic Stem CellsNCT03659773Hospices Civils de Lyon152
终止
2 期
Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)Hematological MalignanciesNCT01139164Medical University of South Carolina78
已完成
3 期
Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly PatientsHematologic NeoplasmsNCT02623309Institut Paoli-Calmettes108
已完成
2 期
Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAADyskeratosis CongenitaAplastic AnemiaNCT00455312Masonic Cancer Center, University of Minnesota36